Mode
Text Size
Log in / Sign up
N/A N=23 Supportive Care

Assessment of New Enhanced Ostomy Device in Real-life Settings in Subjects Having a Stoma

Ileostomy - Stoma · Colostomy Stoma

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Trans Epidermal Water Loss — 39.0; 35.9 g/m^2/h

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Test Product A (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Coloplast A/S
Primary completion
Mar 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Trans Epidermal Water Loss
39.0; 35.9

Summary

The study investigates the performance of a new adhesive with regard to the skin condition

Eligibility Criteria

Inclusion Criteria

  • Have given written informed consent
  • Have an ileostomy or a colostomy with liquid* output (as their usual output)
  • Be at least 18 years of age and have full legal capacity
  • Have had their stoma for at least three months
  • Be able to use products with max cut size 45 mm
  • Have self-reported problems with leakage** (three times within 14 days)
  • Handle the Clinical App, test product and comparator product themselves
  • Use a flat SenSura® Mio or a flat SenSura® with standard adhesive as their current product
  • Minimum change of baseplate at least once every 3rd day
  • Are willing and suitable (determined by investigator/study nurse) to use the test product and comparator without using a paste/mouldable ring during the investigation
  • Are willing and suitable (determined by investigator/study nurse) to use a 1-piece product during the investigation

Exclusion Criteria

  • Are currently receiving or have within the past two months received radio-and/or chemotherapy (low doses chemotherapy are allowed for other indications than cancer, e.g. below 15 mg methotrexate for rheumatoid arthritis)
  • Are currently receiving or have within the past month received topical steroid treatment in the peristomal skin area (e.g. lotion or spray) or systemic treatment* (e.g. injection or tablets).
  • Get a positive result of a pregnancy test for women of childbearing age/fertile (**clarified in section 6.3.2)
  • Are breast feeding
  • Are participating in other interventional clinical investigations or have previously participated in this investigation

Exception:

Participation in other Coloplast in-house clinical investigations is accepted under the circumstances that the subject has paused the activities in the investigation and are otherwise complying with the inclusion and exclusion criteria of this (CP300) protocol.

  • Have known hypersensitivity towards any of the products used in the investigation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03770078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search